Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830151 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
A Phase 1 study of Primary Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03830151: Recruiting Phase 1 study of Primary Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT03830151 is a Phase 1 study of Primary Brain Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03830151, a Phase 1 study of Primary Brain Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.
Primary Outcome
The kpl values will be calculated for each biopsy site, tumor border zone, and the contralateral side.
Conditions Studied
Interventions
- DRUG Hyperpolarized Carbon C 13 Pyruvate
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT03830151 shows while recruiting
NCT03830151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Primary Brain Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Carbon C 13 Pyruvate is the first listed.
NCT03830151 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03830151 about?
NCT03830151 is a clinical study titled "Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors". This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers b...
What is the current status of trial NCT03830151?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-05-16. Estimated completion is 2028-12-31.
What conditions does trial NCT03830151 study?
This clinical trial studies the following conditions: Primary Brain Neoplasm.
What interventions are being tested in trial NCT03830151?
The interventions under investigation include: Hyperpolarized Carbon C 13 Pyruvate (DRUG), Magnetic Resonance Spectroscopic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03830151?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03830151 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03830151's enrollment target sits among peer trials
13 1848th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- NCT04879121 · 13 participants · Phase 2
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI